A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist - Zoladex

A. Cassano, A. Astone, C. Garufi, M. R. Noviello, F. Pietrantonio, C. Barone

Research output: Contribution to journalArticlepeer-review

Abstract

Luteinising hormone releasing hormone (LHRH) agonists are currently undergoing clinical trials in the treatment of advanced breast cancer in pre-menopausal women. Clinical responses are attributed to the suppression of the pituitary-ovarian axis, with a reduction in circulating levels of gonadal steroids similar to that produced by castration. In the present case report, we report a partial response to a LHRH analogue in a post-menopausal woman refractory to other endocrine treatments. This response cannot be explained with a chemical castration and confirms the possible direct antitumor effect of Zoladex.

Original languageEnglish
Pages (from-to)123-124
Number of pages2
JournalCancer Letters
Volume48
Issue number2
DOIs
Publication statusPublished - Nov 30 1989

Keywords

  • advanced breast cancer
  • Zoladex

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Fingerprint Dive into the research topics of 'A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist - Zoladex'. Together they form a unique fingerprint.

Cite this